6-iodo-hexa-1,2-diene | 69543-14-2

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机碘化物
• 英文名称: 6-iodo-hexa-1,2-diene
• 英文别名: 6-iodo-1,2-hexadiene；6-iodohexa-1,2-diene；6-Iod-1,2-hexadien
• CAS: 69543-14-2
• 化学式: C₆H₉I
• 分子量: 208.042
• InChiKey: MBJSBEWLCQLVEA-UHFFFAOYSA-N

物化性质

• 沸点：
  176.2±10.0 °C(Predicted)
• 密度：
  1.484±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  7
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  6-iodo-hexa-1,2-diene 在 氢氧化钾 、 sodium hydroxide 、 氯化亚砜 、 Acylase I (Aspergillus 、 silver trifluoromethanesulfonate 、 potassium 2-methylbutan-2-olate 、 三乙胺 、 柠檬酸 作用下， 以 乙醇 、 二氯甲烷 、 水 、 溶剂黄146 、 甲苯 为溶剂， 反应 124.0h， 生成 methyl (2S,6RS)-6-acetoxy-2-<<2-(methoxycarbonyl)acetyl>amino>-7-octenoate
  参考文献：
  名称：

  Macrolactamization via Palladium .pi.-Allyl Alkylation. Preparation of CGS25155: A 10-Membered Lactam Neutral Endopeptidase 24.11 Inhibitor

  摘要：

  DOI：

  10.1021/jo00125a056
• 作为产物：
  描述：

  6-chloro-1,2-hexadiene 在 sodium iodide 作用下， 以83%的产率得到6-iodo-hexa-1,2-diene
  参考文献：
  名称：

  Macrolactamization via Palladium .pi.-Allyl Alkylation. Preparation of CGS25155: A 10-Membered Lactam Neutral Endopeptidase 24.11 Inhibitor

  摘要：

  DOI：

  10.1021/jo00125a056

文献信息

• Rhodium-Catalyzed Regio- and Enantioselective Addition of <i>N</i>-Hydroxyphthalimide to Allenes: A Strategy To Synthesize Chiral Allylic Alcohols
  作者：Zi Liu、Bernhard Breit

  DOI：10.1021/acs.orglett.7b03709

  日期：2018.1.5

  We achieved the first Rh-catalyzed regio- and enantioselective additions of N-hydroxyphthalimide to allenes. This transformation is accomplished via mild reaction conditions, leveraging on Josiphos SL-J003-2 as a chiral ligand to furnish branched O-allyl compounds in good yields with moderate to excellent enantioselectivities. The substrate scope is broad, and various functional groups are tolerated

  我们实现了N-羟基邻苯二甲酰亚胺向丙二烯的第一个Rh催化的区域和对映选择性加成。该转化是通过温和的反应条件完成的，利用Josiphos SL-J003-2作为手性配体，以高收率和中等至出色的对映选择性提供支链的O-烯丙基化合物。底物范围广，并且容许各种官能团。通过转化为具有不同官能团的烯丙基醇以及手性O-烯丙基羟胺，可以详细说明该方法的实用性。
• Morpholine type cinnamide compound
  申请人：Kimura Teiji

  公开号：US20070117798A1

  公开（公告）日：2007-05-24

  The present invention relates to a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein R 1 , R 2 , R 3 , and R 4 are the same or different and each represent a hydrogen atom or a C1-6 alkyl group; X 1 represents a C1-6 alkylene group that may be substituted; X a represents a methoxy group or a fluorine atom; X b represents an oxygen atom or a methylene group, provided that X b is only an oxygen atom when X a is a methoxy group; and Ar 1 represents an aryl group, pyridinyl group, aryloxy group, or pyridinyloxy group that may have a substituent such as a halogen atom; and to use of the compound or salt as a pharmaceutical agent.

  本发明涉及一种由式(I)表示的化合物或其药理学上可接受的盐，其中R1、R2、R3和R4相同或不同，并且每个代表氢原子或C1-6烷基基团；X1代表可能被取代的C1-6烷基基团；Xa代表甲氧基团或氟原子；Xb代表氧原子或亚甲基基团，前提是当Xa为甲氧基团时，Xb仅为氧原子；Ar1代表可能具有卤素原子等取代基的芳基、吡啶基、芳氧基或吡啶氧基；以及将该化合物或盐用作药物剂的用途。
• Spectres de masse de composes alleniques—I
  作者：S. Arseniyadis、J. Gore、M.L. Roumestant

  DOI：10.1016/0040-4020(79)80073-3

  日期：1979.1

  heteroatomic group (hydroxy, alcoxy, halogen, dialkylamino) or a phenyl in the γ position exhibits a strong peak corresponding to the loss of C2H4 (28a.m.u.) from the molecular ion. This is commonly the base peak of the spectra and due to a McLafferty type transfer of the heteroatom or phenyl group to the central allenic carbon atom. The methyl group shows a lower migratory aptitude in such a process. This

  被在γ位上带有杂原子基团（羟基，烷氧基，卤素，二烷基氨基）或苯基的烃链取代的烯丙基化合物的质谱表现出与C 2 H 4损失相对应的强峰（28a.mu）来自分子离子。这通常是光谱的基峰，这是由于杂原子或苯基基团向中心烯丙碳原子的麦克拉费蒂型转移。在这种过程中，甲基显示出较低的迁移能力。在γ-卤素和γ-羟基酮，烯烃，炔烃或芳烃的光谱中未观察到涉及杂原子基团迁移的这种类型的断裂，并且似乎是烯丙基键的特征。提出了杂原子基团（或苯基）对中心烯丙基碳原子的亲核攻击。
• Two cyclic cinnamide compound
  申请人：Kimura Teiji

  公开号：US20070117839A1

  公开（公告）日：2007-05-24

  The present invention relates to a novel two cyclic cinnamide compound and a pharmaceutical agent comprising the compound as an active ingredient. The two cyclic cinnamide compound represented by the general formula (I): wherein represents a single bond or a double bond; Ar 1 represents a phenyl group or pyridinyl group that may be substituted with 1 to 3 substituents; R 1 and R 2 each represent a C1-6 alkyl group, a hydroxyl group, or the like; Z 1 represents a methylene group or vinylene group, which may be substituted with 1 or 2 substituents selected from Substituent Group A1, an oxygen atom, or an imino group that may be substituted with a substituent selected from Substituent Group A1; and p, q, and r each represent an integer of 0 to 2, which has an effect of reducing Aβ40 and Aβ42 production, and thus is particularly useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ such as Alzheimer's disease or Down's syndrome.

  本发明涉及一种新型的二环丙烯酰胺化合物和包含该化合物作为活性成分的药物。所述二环丙烯酰胺化合物由通式（I）表示：其中，表示单键或双键；Ar1表示苯基或吡啶基，可以被1至3个取代基取代；R1和R2分别表示C1-6烷基、羟基或类似物；Z1表示亚甲基或乙烯基，可以被从取代基A1中选择的1或2个取代基、氧原子或取代基A1选择的亚胺基取代；p、q和r分别表示0至2的整数，具有降低Aβ40和Aβ42生成的作用，因此特别适用于作为预防或治疗Aβ引起的神经退行性疾病，如阿尔茨海默病或唐氏综合症的药物。
• TWO CYCLIC CINNAMIDE COMPOUND
  申请人：Kimura Teiji

  公开号：US20090181945A1

  公开（公告）日：2009-07-16

  The present invention relates to a novel two cyclic cinnamide compound and a pharmaceutical agent comprising the compound as an active ingredient. The two cyclic cinnamide compound represented by the general formula (I): wherein represents a single bond or a double bond; Ar 1 represents a phenyl group or pyridinyl group that may be substituted with 1 to 3 substituents; R 1 and R 2 each represent a C1-6 alkyl group, a hydroxyl group, or the like; Z 1 represents a methylene group or vinylene group, which may be substituted with 1 or 2 substituents selected from Substituent Group A1, an oxygen atom, or an imino group that may be substituted with a substituent selected from Substituent Group A1; and p, q, and r each represent an integer of 0 to 2, which has an effect of reducing Aβ40 and Aβ42 production, and thus is particularly useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ such as Alzheimer's disease or Down's syndrome.

  本发明涉及一种新型的双环肉桂酰胺化合物和一种以该化合物为活性成分的药物制剂。该双环肉桂酰胺化合物由通式（I）表示：其中，表示单键或双键；Ar1表示苯基或吡啶基，可以用1至3个取代基取代；R1和R2各表示C1-6烷基、羟基或类似物；Z1表示亚甲基或乙烯基，可以用来自取代基A1的1或2个取代基、氧原子或可用取代基A1取代的亚胺基取代；p、q和r各表示0至2的整数，具有减少Aβ40和Aβ42产生的作用，因此特别适用于作为预防或治疗Aβ引起的神经退行性疾病，如阿尔茨海默病或唐氏综合症的药物制剂。